CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 20 PAGES: 37

More Info
									           CEL-SCI Corporation (CVM) - Financial and Strategic SWOT Analysis
                                        Review
        Reference Code: GDPH37979FSA                                                                                          Publication Date: JAN 2013

          Suite 802, 8229 Boone Boulevard                    Phone              +1 703 5069460                  Revenue          1 (million USD)
          Vienna, VA                                         Fax                +1 703 5069471                  Net Profit       -15.48 (million USD)
          22182                                              Website            www.cel-sci.com                 Employees        43
                                                                                CVM [American Stock                              Pharmaceuticals           &
          United States                                      Exchange                                           Industry
                                                                                Exchange]                                        Healthcare

       Company Overview
       CEL-SCI Corporation (CEL-SCI) is a biotechnology company. It focuses on the research and development of immunotherapy
       products for the treatment of cancer and infectious diseases. The company’s product portfolio comprises of Multikine (Leukocyte
       Interleukin, Injection) investigational cancer therapy being developed in three indications (head and neck cancer; cervical cancer;
       and enhancement of radiation/chemotherapy); and LEAPS technology being developed for the treatment of H1NI1 Flu,
       rheumatoid arthritis and others including malaria, viral encephelities and herpes. Multikine helps in stimulating the immune
       system, thus defending cancer.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      CEL-SCI Corporation, SWOT Analysis
         Maximilian de Clara                 Director                                 Strengths                              Weaknesses
         Geert R. Kersten                    Chief Executive Officer
                                                                                      Intellectual Property                  Substantial Losses
         C. Richard Kinsolving               Director
                                                                                      Sturdy Research and                    FDA Warning Letter
         Peter R. Young                      Director
                                                                                      Development Activities
         Alexander G. Esterhazy              Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strategic Collaborations and           Non-compliance of Government
         CEL-SCI Corporation                                                          Agreements                             Regulations
        Share Price (USD) as on 15-Jan-                                  0.28         Demographics Trends                    Uncertain R&D Outcomes
        2013
        EPS (USD)                                                         NA
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                           77        GlobalData

        Enterprise Value (million USD)                                     74
        Shares Outstanding (million)                                     273
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Dec 14, 2012         CEL-SCI Reports Fiscal 2012 Results
                                                                                      Aug 09, 2012         CEL-SCI Reports Q3 Fiscal 2012 Results
                                                                                      May 10, 2012         CEL-SCI Reports Q2 Fiscal 2012 Results
                                                                                      Feb 09, 2012         CEL-SCI Reports Q1 Fiscal 2012 Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




CEL-SCI Corporation (CVM) - Financial and Strategic SWOT                                                                       Reference Code: GDPH37979FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       CEL-SCI Corporation - Key Facts ...................................................................................................................................................... 5
       CEL-SCI Corporation - Key Employees.............................................................................................................................................. 6
       CEL-SCI Corporation - Key Employee Biographies ........................................................................................................................... 7
       CEL-SCI Corporation - Major Products and Services ......................................................................................................................... 8
       CEL-SCI Corporation - Pharmaceutical Pipeline Products Data ........................................................................................................ 9
          CEL-SCI Corporation, Pipeline Products by Therapy Area ............................................................................................................. 9
          CEL-SCI Corporation, Pipeline Products by Development Phase ................................................................................................ 10
       CEL-SCI Corporation - History ......................................................................................................................................................... 12
       CEL-SCI Corporation - Company Statement .................................................................................................................................... 14
       CEL-SCI Corporation - Locations And Subsidiaries ......................................................................................................................... 16
          Head Office ................................................................................................................................................................................... 16
       Section 2 – Company Analysis ......................................................................................................................................................... 17
       CEL-SCI Corporation - Business Description ................................................................................................................................... 17
       CEL-SCI Corporation - SWOT Analysis ........................................................................................................................................... 18
          SWOT Analysis - Overview........................................................................................................................................................... 18
          CEL-SCI Corporation - Strengths ................................................................................................................................................. 18
             Strength - Intellectual Property .................................................................................................................................................. 18
             Strength - Sturdy Research and Development Activities ........................................................................................................... 18
             Strength - Lead Product: Multikine and Innovative Technology ................................................................................................ 18
          CEL-SCI Corporation - Weaknesses ............................................................................................................................................ 19
             Weakness - Substantial Losses ................................................................................................................................................ 19
             Weakness - FDA Warning Letter ............................................................................................................................................... 19
          CEL-SCI Corporation - Opportunities ........................................................................................................................................... 19
             Opportunity - Strategic Collaborations and Agreements ........................................................................................................... 19
             Opportunity - Demographics Trends ......................................................................................................................................... 19
             Opportunity - Market Potential: Head and neck Cancer ............................................................................................................ 20
             Opportunity - Biotech Focus ...................................................................................................................................................... 20
          CEL-SCI Corporation - Threats ..................................................................................................................................................... 20
             Threat - Non-compliance of Government Regulations .............................................................................................................. 20
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 20
             Threat - Competitive Pressures ................................................................................................................................................. 21
       CEL-SCI Corporation - Key Competitors .......................................................................................................................................... 22
       Section 3 – Company Financial Ratios ............................................................................................................................................. 23
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 23
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 23
       Performance Chart ........................................................................................................................................................................... 25
       Financial Performance...................................................................................................................................................................... 25
       Financial Ratios - Interim Ratios....................................................................................................................................................... 26
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 27
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 28
          CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .......................................................... 28


CEL-SCI Corporation (CVM) - Financial and Strategic SWOT                                                                                                       Reference Code: GDPH37979FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          CEL-SCI Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .......................................................... 29
       CEL-SCI Corporation, Recent Deals Summary ................................................................................................................................ 30
       Section 5 – Company’s Recent Developments ................................................................................................................................ 31
          CEL-SCI Corporation, Recent Developments ............................................................................................................................... 31
             Dec 14, 2012: CEL-SCI Reports Fiscal 2012 Results ............................................................................................................... 31
             Aug 09, 2012: CEL-SCI Reports Q3 Fiscal 2012 Resu
								
To top